Detalles de la búsqueda
1.
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
Cancer
; 130(11): 1940-1951, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38288862
2.
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.
Lancet Oncol
; 20(8): 1148-1159, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31296491
3.
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
BMC Cancer
; 18(1): 1292, 2018 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30591028
4.
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
Eur J Cancer
; 186: 172-184, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37086595
5.
Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma.
Int J Radiat Oncol Biol Phys
; 114(3): 422-432, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35850363
6.
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
J Clin Oncol
; 40(22): 2479-2490, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35394800
Resultados
1 -
6
de 6
1
Próxima >
>>